Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Boston Scientific Corporation

Stage 4 · Declining · week 3

As of Oct 22, 2026, Boston Scientific is in Stage 4, the downtrend phase, now in week 3 (since Oct 7, 2026). It closed at $46.01, 56.2% below its 52-week high and below its 200-day average, which is falling.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about the company

$46.01
+3.39% today
$66.7B · Large cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is BSX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S3 15w
S2 72w
S2 18w
S4 46w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 15w → S2 72w → S3 5w → S2 18w → S3 3w → S4 46w → S1 5w → S4 2w current
Total tracked: 166 weeks across 8 stage runs.

BSX among Medical Devices91st of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
…91BSXStage 4 · wk 322+3.1%
vs 52W High
-56.2%
$41.58 lo$104.98 hi
56.2% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 3
1w13w26w
Week 3, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-20.8%
200 DMA: $58.09 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.86x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
→
Short-term trend flat
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+3.1%
3M
+4.0%
6M
-30.0%
YTD
-51.4%
1Y
-53.9%
Scan Membership
Breakout Watch
Latest: 2025-05-22
10 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 3 · Vol 0.86x
2026-10-21S4
Wk 3 · Vol 0.74x
2026-10-20S4
Wk 2 · Vol 0.84x
2026-10-19S4
Wk 2 · Vol 0.73x
2026-10-16S4
Wk 2 · Vol 0.65x
2026-10-15S4
Wk 2 · Vol 0.82x
2026-10-14S4
Wk 2 · Vol 0.78x
2026-10-13S4
Wk 1 · Vol 0.73x
2026-10-12S4
Wk 1 · Vol 0.69x
2026-10-09S4
Wk 1 · Vol 0.66x
2026-10-08S4
Wk 1 · Vol 1.12x
2026-10-07S41→4
Wk 1 · Vol 0.77x
Moving averages & range
50 DMA
$45.66
200 DMA
$58.09
52W High
$104.98
52W Low
$41.58
5D Low
$44.39
Resistance levels (recent highs)
20d High
$46.01
60d High
$52.01
120d High
$57.78
250d High
$104.98
Next resistance
+13.0%
to 60d High
P/E (TTM)
18.6
Forward 13.6
Earnings Growth (YoY)
+15.1%
Revenue +7.5%
ROE
+15.3%
Profit margin +17.5%
Dividend Yield
0.00%
P/B 2.7

Boston Scientific: quick answers

What stage is Boston Scientific in?

As of Oct 22, 2026, Boston Scientific (BSX) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 7, 2026 and is in week 3. What the four stages mean

Is Boston Scientific in an uptrend?

No. Boston Scientific is in a Stage 4 downtrend. It trades 20.8% below its 200-day average, which is falling.

How far is Boston Scientific from its 52-week high?

Boston Scientific closed at $46.01 on Oct 22, 2026, 56.2% below its 52-week high of $104.98. Its 52-week low is $41.58.

How has Boston Scientific performed over the past year?

As of Oct 22, 2026, Boston Scientific is down 53.9% over the past year and down 51.4% so far in 2026.

Which sector and industry is Boston Scientific in?

Boston Scientific is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.